Publication
Clinical evaluation of bevacizumab intravenous infusion-associated bleeding risk and vascular stress under a vascular‑protective management pathway in recurrent ovarian cancer.
Tingting Li, Lili Wan, Xin Wang, Dongyun Wu, Aomei Li, Jixian Zang
Pakistan journal of pharmaceutical sciencesOct 1, 2026PMID 42489315doi:10.36721/PJPS.2026.39.10.300.1 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Oct 1, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261001-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Bevacizumab (BEV) is pivotal for anti-angiogenic therapy in recurrent ovarian cancer (ROC), but its real-world bleeding risk profile and standardized management remain to be refined, demanding tailored pharmacovigilance data for clinical decision-making. OBJECTIVES: This single-center…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Ovarian Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.